Published in J Exp Med on December 19, 2011
Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol (2014) 0.86
Developing epigenetic diagnostics and therapeutics for brain disorders. Trends Mol Med (2013) 0.78
Long noncoding RNAs in viral infections. Virus Res (2015) 0.78
Transcriptional and post-transcriptional regulation of NK cell development and function. Clin Immunol (2016) 0.76
The Cytomegalovirus protein pUL37×1 targets mitochondria to mediate neuroprotection. Sci Rep (2016) 0.75
Enhanced Neuroprotective Effects of Coadministration of Tetrandrine with Glutathione in Preclinical Model of Parkinson's Disease. Parkinsons Dis (2015) 0.75
Commentary: Keeping the batteries charged in Parkinson's disease. CNS Neurol Disord Drug Targets (2012) 0.75
Noncoding RNA Regulation of Dopamine Signaling in Diseases of the Central Nervous System. Front Mol Biosci (2016) 0.75
Neurodegenerative disease: Harnessing virus-mediated mitochondrial protection to combat neurodegeneration. Nat Rev Drug Discov (2012) 0.75
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Transvascular delivery of small interfering RNA to the central nervous system. Nature (2007) 5.21
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Mitochondrial disease. Lancet (2006) 3.38
Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci (2003) 3.30
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord (2006) 2.31
Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. Science (2007) 2.29
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol (1998) 2.20
Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science (2002) 1.40
Assay of mitochondrial functions by resazurin in vitro. Acta Pharmacol Sin (2004) 1.17
Evidence from the anti-idiotypic network that the acetylcholine receptor is a rabies virus receptor. J Virol (1993) 1.11
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J (2001) 1.01
Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur J Neurosci (2007) 0.99
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis (2006) 0.92
The major open reading frame of the beta2.7 transcript of human cytomegalovirus: in vitro expression of a protein posttranscriptionally regulated by the 5' region. J Virol (1998) 0.86
Increased capacity for axonal outgrowth using xenogenic tissue in vitro and in a rodent model of Parkinson's disease. Xenotransplantation (2006) 0.81
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci (2005) 2.34
Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death. Science (2007) 2.29
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J (2002) 2.06
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci U S A (2008) 1.80
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain (2002) 1.75
L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology (2006) 1.66
Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter. J Biol Chem (2006) 1.64
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci (2004) 1.64
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation (2012) 1.59
Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol (2014) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia (2004) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci (2007) 1.50
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
A genome wide linkage disequilibrium screen in Parkinson's disease. J Neurol (2005) 1.41
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. Drugs Today (Barc) (2004) 1.40
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell (2010) 1.32
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A (2009) 1.32
Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. J Gen Virol (2009) 1.31
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res (2010) 1.28
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain (2008) 1.28
The heterogeneity of idiopathic Parkinson's disease. J Neurol (2002) 1.28
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27
Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science (2013) 1.27
Yeast aconitase in two locations and two metabolic pathways: seeing small amounts is believing. Mol Biol Cell (2005) 1.26
Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci (2006) 1.23
Habitual versus goal-directed action control in Parkinson disease. J Cogn Neurosci (2010) 1.22
The UL144 gene product of human cytomegalovirus activates NFkappaB via a TRAF6-dependent mechanism. EMBO J (2006) 1.22
Immunosenescence and Cytomegalovirus: where do we stand after a decade? Immun Ageing (2010) 1.22
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain (2006) 1.20
Report from the second cytomegalovirus and immunosenescence workshop. Immun Ageing (2011) 1.19
Health-related quality of life in Huntington's disease: Which factors matter most? Mov Disord (2009) 1.19
Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development (2013) 1.18
Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplant (2003) 1.17
GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro. Exp Neurol (2003) 1.17
A pathophysiological model of freezing of gait in Parkinson's disease. Parkinsonism Relat Disord (2008) 1.17
Folding of fumarase during mitochondrial import determines its dual targeting in yeast. J Biol Chem (2003) 1.16
The current clinical management of Huntington's disease. Mov Disord (2008) 1.16
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain (2008) 1.15
Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett (2005) 1.15
Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia (2008) 1.15
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord (2009) 1.14
Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord (2012) 1.14
Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord (2004) 1.14
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain (2003) 1.13
Huntington's disease patients have selective problems with insight. Mov Disord (2006) 1.12
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J Neurosci (2005) 1.12
Lytic infection of permissive cells with human cytomegalovirus is regulated by an intrinsic 'pre-immediate-early' repression of viral gene expression mediated by histone post-translational modification. J Gen Virol (2009) 1.11
The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. Exp Neurol (2008) 1.11
Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nat Clin Pract Neurol (2007) 1.11
Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport (2004) 1.10
Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci (2003) 1.10
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol (2005) 1.09
The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry (2009) 1.09
Role for bovine viral diarrhea virus Erns glycoprotein in the control of activation of beta interferon by double-stranded RNA. J Virol (2004) 1.08
Human cytomegalovirus latency alters the cellular secretome, inducing cluster of differentiation (CD)4+ T-cell migration and suppression of effector function. Proc Natl Acad Sci U S A (2012) 1.07
Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia (2003) 1.06
Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets (2008) 1.05
Health-related quality of life in Huntington's disease: a comparison of two generic instruments, SF-36 and SIP. Mov Disord (2004) 1.05
White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage (2012) 1.04
Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsychologia (2002) 1.02
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs (2006) 1.01
The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. Neuropsychologia (2010) 1.01
Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell (2012) 1.01
Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis (2012) 1.00
Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology (2013) 1.00
Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci (2002) 0.99
Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4⁺ T cells. PLoS Pathog (2013) 0.99
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry (2010) 0.98
Top-down attentional control in Parkinson's disease: salient considerations. J Cogn Neurosci (2010) 0.98
The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain (2012) 0.97
Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res (2007) 0.97
Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease. Brain (2008) 0.97
Cell therapy in Huntington disease. Neurosurg Focus (2008) 0.97
Translation-coupled translocation of yeast fumarase into mitochondria in vivo. J Biol Chem (2007) 0.96
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry (2013) 0.96
Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. Cell Cycle (2009) 0.95
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord (2011) 0.95